Literature DB >> 11160031

The importance of diagnosing genital herpes.

M Cusini1, M Ghislanzoni.   

Abstract

Genital herpes is the result of infection by herpes simplex virus type 2 (HSV-2) and, to a lesser extent, HSV-1. Recent years have seen a rise in the prevalence of genital HSV infection in both industrialized and developing countries. The main factors attributed to the spread of HSV infection include asymptomatic virus shedding, and under-recognition and under-diagnosis of the disease. At the level of the individual patient, genital herpes is associated with significant psychosocial morbidity and complications such as neonatal herpes, the result of transmission of HSV from mother to baby. HSV-2 infection is also implicated in the transmission and acquisition of human immunodeficiency virus (HIV). As genital HSV infection has substantial public health implications, increased awareness of the disease and its prevalence, together with better use of diagnostic tests, may be one step towards more effective management and infection control.

Entities:  

Mesh:

Year:  2001        PMID: 11160031     DOI: 10.1093/jac/47.suppl_1.9

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Infection status of human parvovirus B19, cytomegalovirus and herpes simplex Virus-1/2 in women with first-trimester spontaneous abortions in Chongqing, China.

Authors:  Ya-Ling Gao; Zhan Gao; Miao He; Pu Liao
Journal:  Virol J       Date:  2018-04-23       Impact factor: 4.099

2.  Recurrent antiviral-resistant genital herpes in an immunocompetent patient.

Authors:  John D Kriesel; Spotswood L Spruance; Mark Prichard; Jacqueline N Parker; Earl R Kern
Journal:  J Infect Dis       Date:  2005-05-27       Impact factor: 5.226

3.  Seropositivity and determinants of immunoglobulin-G (IgG) antibodies against Herpes simplex virus (HSV) types -1 and -2 in pregnant women in Port Harcourt, Nigeria.

Authors:  Iheanyi Omezuruike Okonko; Tochi Ifeoma Cookey
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

4.  A population based study of herpes simplex virus 2 seroprevalence in rural Costa Rica.

Authors:  A C Rodríguez; P E Castle; J S Smith; C Bratti; A Hildesheim; M Schiffman; R Viscidi; R D Burk; R L Ashley; X Castellsagué; R Herrero
Journal:  Sex Transm Infect       Date:  2003-12       Impact factor: 3.519

5.  Atypical genital herpes: report of five cases.

Authors:  Anneli Uusküla; Elve Raukas
Journal:  Scand J Infect Dis       Date:  2004

6.  Herpes simplex virus type-2 seropositivity among ever married women in South and north Vietnam: a population-based study.

Authors:  Hoa Van Le; Victor J Schoenbach; Rolando Herrero; Anh Thi Hoang Pham; Hieu Trong Nguyen; Thuy Thi Nguyen; Nubia Muñoz; Silvia Franceschi; Salvatore Vaccarella; Max D Parkin; Peter J F Snijders; Rhoda Ashley Morrow; Jennifer S Smith
Journal:  Sex Transm Dis       Date:  2009-10       Impact factor: 2.830

7.  Use of commercial enzyme immunoassays to detect antibodies to the herpes simplex virus type 2 glycoprotein G in a low-risk population in Hanoi, Vietnam.

Authors:  Thoai D Ngo; Oliver Laeyendecker; Hanh La; Wayne Hogrefe; Rhoda Ashley Morrow; Thomas C Quinn
Journal:  Clin Vaccine Immunol       Date:  2007-12-12

8.  Seroprevalence and Influence of Torch Infections in High Risk Pregnant Women: A Large Study from South India.

Authors:  K Rebekah Prasoona; B Srinadh; T Sunitha; M Sujatha; M L N Deepika; B Vijaya Lakshmi; Aruna Ramaiah; A Jyothy
Journal:  J Obstet Gynaecol India       Date:  2014-10-29

9.  Suppressive valacyclovir therapy to reduce genital herpes transmission: good public health policy?

Authors:  Paul E Bonnar
Journal:  Mcgill J Med       Date:  2009-01

Review 10.  Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and prevention.

Authors:  Elena Anzivino; Daniela Fioriti; Monica Mischitelli; Anna Bellizzi; Valentina Barucca; Fernanda Chiarini; Valeria Pietropaolo
Journal:  Virol J       Date:  2009-04-06       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.